XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended
June 30,		Six Months Ended
June 30,
 2020201920202019
Net product revenue$5,077.7  $5,168.7  $10,481.2  $9,861.0  
Collaboration and other revenue (1)
421.7  468.0  878.0  867.9  
Revenue$5,499.4  $5,636.7  $11,359.2  $10,728.9  
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $34.7 million and $70.0 million during the three and six months ended June 30, 2020, respectively, and $59.6 million and $95.1 million during the three and six months ended June 30, 2019, respectively.
The following table summarizes revenue by product for the three months ended June 30, 2020 and 2019:
Three Months Ended
June 30,
 20202019
United States (U.S.)(1)
Outside U.S.Total
U.S.(1)
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$952.5  $277.2  $1,229.8  $792.1  $236.4  $1,028.5  
Humalog® (2)
281.7  273.3  555.1  396.1  281.5  677.6  
Humulin®
214.3  99.3  313.6  220.1  102.6  322.6  
Basaglar®
229.7  60.7  290.4  232.2  58.6  290.7  
Jardiance (3)
145.1  116.9  262.0  142.6  89.3  231.9  
Trajenta (4)
16.4  60.5  76.8  64.5  89.5  153.9  
Other Diabetes33.6  17.8  51.3  35.2  21.6  57.1  
Total Diabetes1,873.3  905.7  2,779.0  1,882.8  879.5  2,762.3  
Oncology:
Alimta®
317.2  221.9  539.1  341.7  236.1  577.8  
Cyramza®
94.1  162.7  256.7  89.8  152.0  241.8  
Verzenio®
141.7  66.9  208.6  105.2  28.7  133.9  
Erbitux®
115.8  13.7  129.5  136.9  22.4  159.3  
Other Oncology13.9  120.7  134.7  16.2  68.2  84.4  
Total Oncology682.7  585.9  1,268.6  689.8  507.4  1,197.2  
Immunology:
Taltz®
289.2  106.0  395.2  268.1  85.7  353.8  
Olumiant®
13.2  131.8  145.0  10.7  91.7  102.4  
Other Immunology8.1  —  8.1  —  —  —  
Total Immunology310.5  237.8  548.3  278.8  177.3  456.1  
Neuroscience:
Cymbalta®
7.7  172.1  179.9  18.1  169.0  187.2  
Zyprexa®
9.1  87.5  96.6  9.3  95.1  104.3  
Emgality®
80.6  6.8  87.4  33.8  0.5  34.3  
Other Neuroscience6.6  52.1  58.6  43.2  83.7  126.9  
Total Neuroscience104.0  318.5  422.5  104.4  348.3  452.7  
Other:
Forteo®
119.6  133.0  252.7  172.8  188.0  360.8  
Cialis®
23.4  107.3  130.7  35.1  165.1  200.2  
Other31.4  66.4  97.6  88.8  118.6  207.4  
Total Other174.4  306.7  481.0  296.7  471.7  768.4  
Revenue$3,144.8  $2,354.6  $5,499.4  $3,252.5  $2,384.2  $5,636.7  
Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Humalog revenue includes insulin lispro.
(3) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(4) Trajenta revenue includes Jentadueto®.
The following table summarizes revenue by product for the six months ended June 30, 2020 and 2019:
Six Months Ended
June 30,
 20202019
U.S. (1)
Outside U.S.Total
U.S. (1)
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity$1,882.0  $577.1  $2,459.1  $1,457.7  $450.6  $1,908.3  
Humalog (2)
680.3  570.5  1,250.8  844.8  563.7  1,408.4  
Humulin428.4  200.8  629.3  421.3  199.0  620.3  
Basaglar460.1  134.0  594.1  430.3  111.8  542.1  
Jardiance (3)
289.7  239.8  529.5  267.8  167.7  435.5  
Trajenta (4)
45.1  124.9  170.0  111.8  174.0  285.9  
Other Diabetes78.9  36.3  115.1  68.5  46.3  114.8  
Total Diabetes3,864.5  1,883.4  5,747.9  3,602.2  1,713.1  5,315.3  
Oncology:
Alimta641.5  457.7  1,099.2  623.5  453.5  1,076.9  
Cyramza183.2  312.5  495.7  164.9  275.2  440.0  
Verzenio271.1  125.6  396.7  198.7  44.6  243.3  
Erbitux233.7  26.7  260.3  250.3  27.5  277.7  
Other Oncology11.1  207.0  218.2  46.3  125.5  172.1  
Total Oncology1,340.6  1,129.5  2,470.1  1,283.7  926.3  2,210.0  
Immunology:
Taltz616.7  222.0  838.7  449.0  157.4  606.3  
Olumiant24.5  260.2  284.7  17.1  167.4  184.5  
Other Immunology10.7  —  10.7  —  —  —  
Total Immunology651.9  482.2  1,134.1  466.0  324.8  790.8  
Neuroscience:
Cymbalta19.3  370.9  390.3  28.4  322.9  351.3  
Zyprexa20.3  174.7  195.0  18.6  193.0  211.5  
Emgality147.9  13.6  161.5  46.0  2.6  48.5  
Other Neuroscience26.7  112.5  139.2  62.5  171.8  234.6  
Total Neuroscience214.2  671.7  886.0  155.5  690.3  845.9  
Other:
Forteo242.2  282.9  525.0  298.7  375.0  673.7  
Cialis49.5  274.3  323.8  178.4  330.0  508.4  
Other110.7  161.5  272.3  158.8  226.2  384.9  
Total Other402.4  718.7  1,121.1  635.9  931.2  1,567.0  
Revenue$6,473.6  $4,885.6  $11,359.2  $6,143.3  $4,585.6  $10,728.9  
Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Humalog revenue includes insulin lispro.
(3) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(4) Trajenta revenue includes Jentadueto..
.
The following table summarizes revenue by geographical area:
Three Months Ended
June 30,		Six Months Ended
June 30,
2020201920202019
Revenue—to unaffiliated customers (1):
U.S. (2)
$3,144.8  $3,252.5  $6,473.6  $6,143.3  
Europe873.0  928.2  1,934.1  1,828.5  
Japan666.7  653.2  1,259.0  1,196.9  
China239.8  230.9  507.1  442.1  
Other foreign countries575.2  571.9  1,185.5  1,118.1  
Revenue$5,499.4  $5,636.7  $11,359.2  $10,728.9  
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
(2) U.S. revenue includes revenue in Puerto Rico.
Schedule of amounts recorded for contract liabilities
The following table summarizes contract liability balances:
 June 30, 2020December 31, 2019
Contract liabilities$299.8  $264.6